- Report
- December 2025
- 200 Pages
Global
From €2619EUR$2,990USD£2,273GBP
- Report
- May 2025
- 136 Pages
Global
From €4160EUR$4,750USD£3,611GBP
- Report
- June 2025
- 150 Pages
Global
From €2364EUR$2,699USD£2,052GBP
- Report
- July 2023
- 115 Pages
Global
From €3372EUR$3,850USD£2,927GBP
- Report
- May 2024
- 200 Pages
Global
From €3635EUR$4,150USD£3,155GBP
- Report
- October 2024
- 318 Pages
Global
From €6963EUR$7,950USD£6,043GBP
- Report
- May 2024
- 130 Pages
Global
From €3502EUR$3,999USD£3,040GBP
Neupro is a brand of central nervous system (CNS) drugs used to treat Parkinson's disease and restless legs syndrome. It is a dopamine agonist, meaning it works by activating dopamine receptors in the brain. Neupro is administered through a transdermal patch, which is applied to the skin and releases the drug over a period of time. The patch is designed to provide a steady, consistent dose of the drug throughout the day.
Neupro is a relatively new drug, having been approved by the US Food and Drug Administration in 2008. It is currently marketed by UCB, a Belgian biopharmaceutical company. Other companies in the CNS drug market include AbbVie, GlaxoSmithKline, Merck, and Pfizer. Show Less Read more
